Vertex Pharmaceuticals has dominated the cystic fibrosis (CF) market and is now expanding into new, high-growth areas. The ...

The Nasdaq Composite Index ( ^IXIC -4.00%) is now squarely in correction territory. But stock market corrections have one key ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

The U.S. Food and Drug Administration recently approved a new class of non-opioid painkiller which one Lowcountry pharmacist is calling “revolutionary.” ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...

Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said, ...

Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...

Investing.com -- Vertex Pharmaceuticals Inc (NASDAQ: VRTX ).’s newly approved non-opioid pain medication, Journavx, has been included in UnitedHealth Group Inc (NYSE: UNH ).’s coverage, according to ...

Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...